Amarin Corp Plcuk (AMRN) EBITDA Margin (2013 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly EBITDA Margin of 28.45% for Q2 2026, down 648.0% year-over-year from 5.19% in Q2 2025, and down 13.3% quarter-over-quarter from 25.11% in Q1 2026.
Amarin Corp Plcuk (AMRN) EBITDA Margin (2013 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported EBITDA Margin for 14 consecutive years, with 28.45% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA Margin fell 648.0% year-over-year to 28.45%; the TTM figure through Jun 2026 stood at 21.89% (up 2845.0% YoY), while the FY2025 annual figure was 23.48%, up 1667.0% from the prior year.
- EBITDA Margin declined to 28.45% in Q2 2026 per AMRN's latest filing, from 25.11% in the prior quarter.
- Across five years, EBITDA Margin topped out at 0.78% in Q2 2024 and bottomed at 84.3% in Q4 2024.
- Historically, EBITDA Margin has averaged 28.95% across 5 years, with a median of 24.57% in 2024.
- Annual changes were most pronounced in 2024 — EBITDA Margin slumped 7782 bps — and 2025, when it jumped 7145 bps.
- Amarin Corp Plc\Uk's EBITDA Margin stood at 10.62% in 2022, then jumped by 39 bps to 6.47% in 2023, then slumped by 1202 bps to 84.3% in 2024, then soared by 85 bps to 12.85% in 2025, then slumped by 121 bps to 28.45% in 2026.
- Business Quant data shows AMRN's EBITDA Margin at 28.45% in Q2 2026, 25.11% in Q1 2026, and 12.85% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 5.72% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -28.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.45% |
| Mar 31, 2026 | -25.11% |
| Dec 31, 2025 | -12.85% |
| Sep 30, 2025 | -22.35% |
| Jun 30, 2025 | -21.98% |
| Mar 31, 2025 | -39.88% |
| Dec 31, 2024 | -84.30% |
| Sep 30, 2024 | -59.50% |
| Jun 30, 2024 | -0.78% |
| Mar 31, 2024 | -24.03% |
| Dec 31, 2023 | -6.47% |
| Sep 30, 2023 | -32.47% |
| Jun 30, 2023 | -29.89% |
| Mar 31, 2023 | -20.17% |
| Dec 31, 2022 | -10.62% |
| Sep 30, 2022 | -5.72% |
| Jun 30, 2022 | -66.53% |
| Mar 31, 2022 | -29.91% |
| Dec 31, 2021 | 11.17% |
| Sep 30, 2021 | -9.20% |